This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Grifols Therapeutics, Inc.
Grifols Therapeutics, Inc., a leading global biotechnology company, is headquartered in the United States and operates extensively across Europe, Latin America, and Asia. Founded in 1909, Grifols has established itself in the biopharmaceutical industry, specialising in the development of innovative therapies derived from human plasma. The company’s core products include immunoglobulins, albumin, and clotting factors, which are essential for treating various medical conditions, including immune deficiencies and bleeding disorders. Grifols is renowned for its commitment to quality and safety, setting industry standards with its advanced manufacturing processes. With a strong market position, Grifols has achieved significant milestones, including the expansion of its global network of plasma collection centres. This strategic growth enhances its ability to deliver life-saving therapies to patients worldwide, solidifying its reputation as a trusted leader in the biopharmaceutical sector.
DitchCarbon Score
How does Grifols Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Grifols Therapeutics, Inc.'s score of 75 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Grifols Therapeutics, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Grifols, S.A., which cascades its emissions data and climate commitments down to Grifols Therapeutics. As part of its climate strategy, Grifols, S.A. has set various reduction targets, although specific details regarding these targets are not provided for Grifols Therapeutics. The company is involved in initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), which are aimed at enhancing transparency and accountability in climate action. While no absolute emissions figures are reported, Grifols Therapeutics is committed to aligning with the broader sustainability goals of its parent company, Grifols, S.A., which focuses on reducing its carbon footprint and improving environmental performance across its operations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 67,369,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 122,508,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 102,600,000 | 00,000,000 | 00,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Grifols Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
